SLC5A2 and type 2 diabetes mellitus: These findings suggest that the early hemodynamic action of SGLT2 inhibitors and resulting regulation of fluid volume are major factors that contribute to the beneficial impact on cardiovascular events in patients with type 2 diabetes and a high risk of CVD, especially for those with HHF [26, 27].